Related Experiment Video

Updated: Jan 26, 2026

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

13.7K

Measurement of β-Arrestin Recruitment at GPCRs Using the Tango Assay

Geneviève Laroche1, Patrick M Giguère2

  • 1Department of Biochemistry, Microbiology and Immunology, University of Ottawa Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada.

Methods in Molecular Biology (Clifton, N.J.)
|April 11, 2019
PubMed

Insights

Researchers developed Tango, a novel transcriptional assay to measure G protein-coupled receptor (GPCR) activation by tracking β-arrestin recruitment. This tool aids in understanding biased signaling for improved drug design.

Area of Science:

  • Pharmacology and Molecular Biology
  • G protein-coupled receptor (GPCR) signaling pathways
  • Drug discovery and development

Background:

  • Intracellular signaling by GPCRs is regulated by G proteins and accessory proteins like arrestins.
  • β-arrestin recruitment is a key indicator of GPCR activation.
  • Functional selectivity (biased signaling) allows ligands to activate specific pathways, offering therapeutic potential.

Purpose of the Study:

  • To introduce a novel transcriptional-based assay for measuring transient β-arrestin recruitment.
  • To provide a tool for interrogating GPCR activation.
  • To facilitate the study of biased signaling in drug discovery.

Main Methods:

  • Development of the Tango assay, a transcriptional reporter system.
  • Utilizing Tango to measure β-arrestin recruitment dynamics at GPCRs.
  • Application of the assay to investigate GPCR activation profiles.

Main Results:

  • Demonstrated the capability of the Tango assay to quantify transient β-arrestin recruitment.
  • Provided a unique platform for interrogating GPCR signaling.
  • Enabled the study of ligand-specific pathway activation.

Conclusions:

  • The Tango assay is a valuable tool for studying GPCR activation and biased signaling.
  • This platform supports the design of more selective drugs with improved therapeutic outcomes.
  • Advances in understanding GPCR pharmacology through novel assay development.
Keywords:
Cell-based assayG protein-coupled receptorGPCRs signalingTangoβ-Arrestin

More Related Videos

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

13.3K
Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

26.2K

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.4K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.6K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.7K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.5K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
850